As you will be aware The Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab with platinum-based chemotherapy for advanced unresectable, recurrent or metastatic previously untreated oesophageal cancer [ID2712] and Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629].
Please note that following on from information received from the company, these appraisals have been combined and will be appraised as one Single Technology Appraisal [ID2712].
The timelines have been revised and the appraisal is now anticipated to begin in mid- January 2022 when we will write to stakeholders about how they can get involved.
| Status | Suspended |
| Decision | Selected |
| Process | TA |
| ID number | 1629 |
Project Team
| Project lead | Michelle Adhemar |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 06 December 2022 | The Department of Health has asked NICE to produce guidance on using the above technology in the NHS in England. The company has informed NICE that it will not provide an evidence submission for this appraisal at this time. Therefore, we are suspending the appraisal while we consider the next steps. NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 05 October 2021 | Suspended. As you will be aware The Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab with platinum-based chemotherapy for advanced unresectable, recurrent or metastatic previously untreated oesophageal cancer [ID2712] and Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]. Please note that following on from information received from the company, these appraisals have been combined and will be appraised as one Single Technology Appraisal [ID2712]. The timelines have been revised and the appraisal is now anticipated to begin in mid- January 2022 when we will write to stakeholders about how they can get involved. |
| 16 April 2021 - 17 May 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 14 July 2020 | Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course. |
| 24 January 2020 | In progress. Topic is in progress |
For further information on our processes and methods, please see our CHTE processes and methods manual